Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
Metrics to compare | MBX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMBXPeersSector | |
---|---|---|---|---|
P/E Ratio | 27.8x | −5.1x | −0.5x | |
PEG Ratio | −0.44 | −0.01 | 0.00 | |
Price/Book | 1.4x | −3.5x | 2.6x | |
Price / LTM Sales | 1.9x | 1.3x | 3.0x | |
Upside (Analyst Target) | 61.3% | 160.9% | 52.6% | |
Fair Value Upside | Unlock | 7.9% | 8.8% | Unlock |